Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Comperat

Showing results (1-10 of 159) with videos related to

Pageof 16
Sort By:
Virchows Archiv : an International Journal of Pathology|May 18, 2016
HOXB13 expression in metastatic prostate cancerJustine Varinot, Eva Comperat
Virchows Archiv : an International Journal of Pathology|September 7, 2024
Variation in cystectomy pathology reporting practice-results from an international survey of 212 pathologistsJon Griffin, Arndt Hartmann, Eva Comperat
BMC Urology|April 9, 2024
"Bone in the penis" or fasciitis ossificans of the penis - a first time description of a pseudo-tumor at an extraordinary siteSebastian Lenart, Oskar Koperek, Anke Scharrer, et al.
BJU International|April 4, 2008
Molecular and histological markers in urothelial carcinomas of the upper urinary tractStephanie Eltz, Eva Comperat, Olivier Cussenot, et al.
European Urology|February 8, 2011
From active surveillance to the concept of secondary preventionOlivier Cussenot, Eva Comperat, Marc-Olivier Bitker, et al.
European Urology|August 22, 2008
Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrumMorgan Rouprêt, David R Yates, Eva Comperat, et al.
Current Urology Reports|July 5, 2015
Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?Johannes Mischinger, Eva Comperat, Christian Schwentner, et al.
Urologic Oncology|March 4, 2019
Therapeutic rationale of targeting BCG and immune checkpoints in non-muscle-invasive bladder cancer: Is this the Future?Andrea K Lindner, Tobias Klatte, Eva Comperat, et al.
Urologic Oncology|September 19, 2009
Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillanceMarie-Dominique Azémar, Eva Comperat, François Richard, et al.
BJU International|October 20, 2022
Total pelvic exenteration surgery for loco-regionally advanced prostate cancer, is it justifiable?Olivier Cussenot, Geraldine Cancel-Tassin, Eva Comperat, et al.
Pageof 16

Showing results (1-10 of 159) with videos related to

Sort By:
Pageof 16
Virchows Archiv : an International Journal of Pathology|May 18, 2016
HOXB13 expression in metastatic prostate cancerJustine Varinot, Eva Comperat
Virchows Archiv : an International Journal of Pathology|September 7, 2024
Variation in cystectomy pathology reporting practice-results from an international survey of 212 pathologistsJon Griffin, Arndt Hartmann, Eva Comperat
BMC Urology|April 9, 2024
"Bone in the penis" or fasciitis ossificans of the penis - a first time description of a pseudo-tumor at an extraordinary siteSebastian Lenart, Oskar Koperek, Anke Scharrer, et al.
BJU International|April 4, 2008
Molecular and histological markers in urothelial carcinomas of the upper urinary tractStephanie Eltz, Eva Comperat, Olivier Cussenot, et al.
European Urology|February 8, 2011
From active surveillance to the concept of secondary preventionOlivier Cussenot, Eva Comperat, Marc-Olivier Bitker, et al.
European Urology|August 22, 2008
Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrumMorgan Rouprêt, David R Yates, Eva Comperat, et al.
Current Urology Reports|July 5, 2015
Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?Johannes Mischinger, Eva Comperat, Christian Schwentner, et al.
Urologic Oncology|March 4, 2019
Therapeutic rationale of targeting BCG and immune checkpoints in non-muscle-invasive bladder cancer: Is this the Future?Andrea K Lindner, Tobias Klatte, Eva Comperat, et al.
Urologic Oncology|September 19, 2009
Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillanceMarie-Dominique Azémar, Eva Comperat, François Richard, et al.
BJU International|October 20, 2022
Total pelvic exenteration surgery for loco-regionally advanced prostate cancer, is it justifiable?Olivier Cussenot, Geraldine Cancel-Tassin, Eva Comperat, et al.
Pageof 16